Menu

New Study Contradicts Previous Idea About Origins of South Americans

Divergent human lineages of North America intermingled before setting off to establish populations of Central and South America.  

Jun 1, 2018
Sukanya Charuchandra

WIKIMEDIA COMMONSThe arrival and migration of human populations across the Americas is more complicated than previous research has suggested. Published today (May 31) in Science, a study proposes that the earliest settlers in the Americas diverged and united multiple times over the course of history, rather than parting ways once and never meeting again, as paleontologists had thought.  

While an initial split between two groups in North America happened between 18,000 and 15,000 years ago, there appears to have been mixing between them around 13,000 years ago. According to a statement by the research group, the two lineages probably mated with each other during their migration into the south. “These two populations split early and were isolated for a few thousand years,” Christina Scheib, an archaeologist at the University of Tartu and coauthor of the paper, tells The Atlantic. “Then, they came back together while growing through South America.”

According to previous research, the first settlers in the Americas split into two groups, the northern and southern. It was believed that people in Central and South America originated from the southern branch. Scheib tells The Atlantic that her team wanted to “fill out this picture by getting as many ancient genomes as we could.”

She and her colleagues analyzed 91 ancient genomes from locations in California and Canada. These sites have been witness to settlements as far back as 13,000 years ago, with the ancient populations characteristic of the two branches. The DNA did not support the theory of a complete separation between the two ancestries. Further, the researchers found that between 42 and 71 percent of present-day Central and South American genomes is representative of the northern branch whose descendent migrated eastward in North America.

“This study is important because it begins to move us away from overly simplistic models of how people first spread throughout the Americas,” Deborah Bolnick, a geneticist at the University of Texas at Austin who was not involved in the study, tells The New York Times.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.